RAPIVAB (peramivir)
RAPIVAB is indicated for the treatment of Influenza.
How RAPIVAB Works
Peramivir is an antiviral that acts as an inhibitor of influenza virus neuraminidase. By binding to and inhibiting this enzyme, the drug prevents the cleavage of sialic acid residues, which is necessary for the release of newly formed virions from infected cells. This action limits the spread of the virus within the respiratory tract.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2014-12-19
- Patent Cliff
- 2027
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
RAPIVAB Approval History
What RAPIVAB Treats
1 indicationsRAPIVAB is approved for 1 conditions since its original approval in 2014. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Influenza
RAPIVAB Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to RAPIVAB
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
9 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05648448 AD ASTRA | VIR22003 | Ph 2 | recruiting | A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza |
| NCT02635724 results posted | BCX1812-306 | Ph 3 | completed | Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza |
| NCT02369159 results posted | BCX1812-305 | Ph 3 | completed | Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza |
| NCT00610935 results posted | BCX1812 311 HHS # O100200700032C | Ph 3 | terminated | Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza |
| NCT02609399 results posted | IRB00080405 1 IDSEP150026-01-00, 1 IDSEP160031-01-00 | Ph 4 | completed | ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir |
| NCT02665351 | Peramivir in adult influenza_1 | Ph 2, Ph 3 | completed | Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections |
| NCT00705406 results posted | BCX1812-212 HHS 0100200700032C | Ph 2 | completed | A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza |
| NCT00957996 results posted | BCX1812-303 HHS 0100200700032C | Ph 3 | completed | Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza |
| NCT01224795 | BCX1812-304 HHS 0100200700032C | Ph 3 | terminated | A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza. |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
RAPIVAB FDA Label Details
Indications & Usage
FDA Label (PDF)RAPIVAB is indicated for the treatment of Influenza.
RAPIVAB Patents & Exclusivity
Patents (2 active)
Pro Intelligence Preview
Deep insights for RAPIVAB
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2027
- • 5 active patents
Trial Analysis
- • 10 total trials
- • Stage: Declining
Competitive Landscape
- • 3 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment